Pharma
Commented by Juliane Zielonka on August 18th, 2022 | 13:50 CEST
Apple, Tocvan Ventures, Valneva - More returns through innovation or risk hedging?
Innovations are hailed as market drivers. The more innovative a company is, the more likely it is to stay ahead of the competition. But this requires loyal customers who also support these innovations. And Apple has just such a customer base, setting a good example that loyalty must be rewarded for innovation. In contrast, pharmaceutical company Valneva has the challenge of exposure to different development cycles in the healthcare market. If only because of the duration of clinical studies, which rightly have to go well before a new product comes onto the market. This time, nature lovers could benefit. Those who find all this too volatile and unpredictable should once again turn to commodities as a hedge. With Tocvan Ventures, a candidate is in the running that looks very closely at optimizing the costs of its operations - to the benefit of investors.
ReadCommented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST
Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?
Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.
ReadCommented by Nico Popp on June 22nd, 2022 | 13:01 CEST
Crisis investments? Pharmaceutical stocks in check: Bayer, XPhyto, Pfizer
Many investors want solid foundations for their portfolios when the market is in turmoil. Pharmaceutical stocks have always been considered largely detached from the overall market - after all, our health is not subject to market cycles. We explain whether this assumption is correct and how investors can now invest in stocks from the sector, using three shares as examples.
ReadCommented by Nico Popp on May 17th, 2022 | 09:54 CEST
Alzheimer's share? Ask the CEO! Valneva, NervGen Pharma, Bayer
High blood pressure, diabetes, stroke and Alzheimer's disease are scourges of our time. As people in industrialized countries grow older, it becomes increasingly likely that they will also suffer from one of these diseases. While there is likely to be a genetic predisposition for all of the ailments mentioned, lifestyle also plays a role. Lack of exercise and obesity often leads first to high blood pressure, then to diabetes, and ultimately to even worse conditions. In the event of a pandemic, all people with such pre-existing conditions belong to a high-risk group. Reason enough to take a closer look at stocks related to these issues and ask how investors can profit.
ReadCommented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST
Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus
Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?
ReadCommented by Nico Popp on May 5th, 2022 | 11:52 CEST
Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva
Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.
ReadCommented by Carsten Mainitz on January 26th, 2022 | 13:34 CET
Valneva, Perimeter Medical Imaging AI, MorphoSys - This is where it gets exciting!
The Corona pandemic still has the world firmly in its grip. The number of new infections is skyrocketing. Nevertheless, the chances are good that the pandemic can be brought under control by means of numerous vaccines. But Corona is not the only scourge. Numerous research efforts are focused on diagnosing, treating and curing cancer. Here, innovative AI-based technologies are increasingly being used to help save lives and significantly reduce costs for the healthcare system.
ReadCommented by André Will-Laudien on August 4th, 2021 | 11:10 CEST
XPhyto Therapeutics - Groundbreaking diagnostic platforms of the future
The number of infectious diseases that we humans are fighting today has increased significantly in recent decades, not just because they have become known and researched. Increasingly frequent variants and neoplasms have also led in turn to entirely new disease patterns. An important area upstream of the medical sector is the large diagnostics market. The umbrella term of diagnostics is used in particular in the context of the detection and differentiation of diseases. This is referred to as clinical diagnostics. Many test and diagnostic procedures are assigned to the bioscience sector since studies must first prove their exact validity. Worldwide, more than 10,000 companies are involved in symptom research, the detection, screening and analysis of the diagnosis of diseases.
ReadCommented by Armin Schulz on July 14th, 2021 | 10:54 CEST
Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?
One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.
ReadCommented by André Will-Laudien on March 2nd, 2021 | 11:15 CET
Q&M Dental, Pfizer, BioNTech, Teva: Watch out for these pharma picks!
The COVID pandemic has permanent surprises in store, which strongly influence our daily life. The province of Tyrol was sealed off entirely 2 weeks ago. The Czech Republic is being helped out with vaccine doses because the incidence figures are going through the roof. In Germany, hairdressers and DIY stores have been allowed to open again. Gradually, everyday life is returning to normal, but it will probably take some time before we regain the quality of life of the pre-Corona years. Let's take a closer look at various business models in the healthcare industry to get a feel for what's next.
Read